

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26

The role of veterinary diagnostic laboratories during COVID-19 response in the United States

Nia Clements¹, Diego G. Diel², François Elvinger², Gary Koretzky³, Julie Siler¹, and Lorin D. Warnick^{2*}

¹ Department of Public and Ecosystem Health, Cornell University, Ithaca, NY, United States

² Department of Population Medicine and Diagnostic Sciences, Cornell University, Ithaca, NY, United States

³ Department of Medicine, Weill Cornell Medicine, New York, NY United States and Department of Microbiology and Immunology, Cornell University, Ithaca, NY

* Corresponding author

Email: ldw3@cornell.edu (LW)

27 **Abstract**

28 Robust testing capacity was necessary for public health agencies to respond to severe acute
29 respiratory syndrome coronavirus 2 (SARS-CoV-2) during the coronavirus disease 19 (COVID-
30 19) pandemic. As the nation faced the need for robust testing capacity, it became necessary to use
31 all possible resources. In many cases, veterinary diagnostic laboratories rose to meet this demand
32 because these facilities routinely perform high throughput diagnostic testing of large animal
33 populations and are typically familiar with pathogens of high pandemic concern. In this study, we
34 evaluated the impact of veterinary diagnostic laboratories in the United States on SARS-CoV-2
35 testing. Results of surveys, semi-structured interviews, and analysis of publicly available
36 information showed that veterinary diagnostic laboratories had a substantial impact on human
37 health through population-level testing in the COVID-19 response, supporting timely and
38 informed public health interventions. This success was not without significant hurdles, as many
39 participating veterinary diagnostic laboratories experienced restriction in their response due to
40 difficulties obtaining the Clinical Laboratory Improvement Amendments (CLIA) certification
41 required to conduct human diagnostic testing. Our results point out the importance of reducing
42 hurdles before the next major public health emergency to enhance access to testing resources
43 overall and to ultimately improve population health.

44 **Introduction**

45 Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) was first detected in Wuhan,
46 Hubei Province, China when numerous cases of atypical pneumonia linked to the Hunan Seafood
47 Market emerged in December of 2019.[1,2] Soon after the initial cases in China, SARS-CoV-2
48 was detected and reported in the United States (US) on January 21, 2020 in Washington State in a

49 patient with respiratory illness.[2] This case was determined to be epidemiologically linked to
50 Wuhan, China.[2] As clinical case numbers mounted, a public health emergency was declared 10
51 days later on January 31 by the United States Department of Health and Human Services.[2] By
52 this time, the disease was rapidly spreading worldwide, triggering mass shutdowns to protect
53 public health while key characteristics of the disease remained unknown.

54 The need for robust SARS-CoV-2 testing was apparent from the pandemic’s start. When the
55 outbreak was in its early stages, testing was concentrated in US major ports of entry to mitigate
56 travel-related spread.[2] The need to expand testing became urgent with evidence for local spread.
57 Additionally, key epidemiological characteristics of the virus were revealed, such as SARS-CoV-
58 2’s early basic reproduction number between 2.2 and 2.7[3] and the high incidence of
59 asymptomatic disease and efficient virus transmission.[1] The emergence of non-travel related
60 cases, coupled with the epidemiological characteristics of SARS-CoV-2, sounded an alarm to the
61 highly infectious nature of the virus and made it clear that broad and aggressive testing would be
62 required to control virus spread. Public health messaging emphasized this point, communicating
63 that testing was necessary to “flatten the epidemic curve,” referring to a strategy of reducing the
64 number of new disease cases by using public health interventions, including testing, so that those
65 infected would be aware and take appropriate measures to prevent viral transmission.[4,5]

66 Countries that incorporated a rigorous testing approach as part of their strategy to “flatten the
67 curve” experienced relative success in controlling and decreasing the spread of the virus. For
68 example, with a population of 51.8 million,[6] South Korea achieved a SARS-CoV-2 testing
69 capacity of 15,000 tests per day early in the pandemic.[4] High testing capacity was achieved
70 through accessible drive-through and walk-in testing sites, allowing for a testing rate of 17,000
71 tests per million people by June 2020.[4] This robust testing approach was a factor among other

72 strategies (e.g. extensive contact tracing, rigid quarantine rules)[7] that prevented the need for
73 lockdowns. South Korea’s public health solution to SARS-CoV-2 consequently had numerous
74 positive downstream effects, such as maintenance of livelihoods in communities and diminishing
75 economic disruption.[4] Given South Korea’s SARS-CoV-2 outcomes, it is clear that effective
76 control was achievable, emphasizing the importance of high testing capacity, among other
77 strategies, in this emergency response.

78 One approach to achieve high testing capacity is through the collaboration of human diagnostic
79 laboratories and veterinary diagnostic laboratories. As stated by the World Organization for
80 Animal Health, veterinary diagnostic laboratories are well suited to supporting testing responses
81 in public health emergencies “because they have experience in quality assurance, biosafety and
82 biosecurity, and high throughput testing for the surveillance and control of infectious diseases in
83 animals, some of which are zoonotic.”[8] Importantly for quality control, veterinary diagnostic
84 laboratories, like human health laboratories, have external accreditors that ensure testing is
85 performed under guidelines that promote accuracy and workforce competence[9] and have
86 Biological Safety Level 2 and 3 facilities to handle diseases of public and animal health
87 concern.[10]

88 In the throes of a public health crisis due to zoonotic infection, veterinary and animal diagnostic
89 laboratories have qualities that may make them more nimble than human health laboratories. For
90 instance, veterinary diagnostic laboratories strive to develop novel testing programs given their
91 familiarity with a wide range of pathogens that have zoonotic potential.[11] Furthermore, animal
92 laboratories have extensive experience in surveilling livestock and poultry for highly pathogenic
93 diseases as threats emerge.[12] Because veterinary diagnostic facilities surveil entire populations
94 of animals to protect the agriculture industry, these laboratories are designed to conduct “herd”

95 testing, whereas human diagnostic laboratories focus on testing individuals. This testing capacity
96 of veterinary laboratories provides a unique opportunity to enable entire populations of humans to
97 be tested in the face of health threats like SARS-CoV-2. Given these characteristics, a
98 collaboration between human health and veterinary diagnostic laboratories can synergize to
99 develop testing programs during pandemics.

100 This potential for collaboration between human diagnostic laboratories and animal diagnostic
101 laboratories is already recognized from a regulatory standpoint, as human-focused diagnostic
102 initiatives can be housed in veterinary diagnostic laboratories with Clinical Laboratory
103 Improvement Amendments (CLIA) certification by the Centers for Medicare and Medicaid
104 Services.[13] For instance, CLIA enabled seven of the sixty member laboratories of the National
105 Animal Health Laboratory Network which is coordinated by the USDA Animal and Plant Health
106 Inspection Service to be certified for human SARS-CoV-2 samples by June 2020, early in the
107 pandemic.[14]

108 The objective of this study was to determine the extent and quantify the impact of SARS-CoV-2
109 testing in veterinary diagnostic laboratories to better understand their role in the SARS-CoV-2
110 response, and to inform decisions for future public health emergencies among veterinary
111 laboratories, human health organizations, and regulatory bodies such as the Centers for Medicare
112 and Medicaid Services.

113 **Materials and methods**

114 **Survey of veterinary diagnostic laboratories**

115 **Source population**

116 Following formal survey approval by the American Association of Veterinary Medical Colleges,
117 an online cross-sectional Qualtrics survey was distributed to American Association of Veterinary
118 Medical Colleges and the National Animal Health Laboratory Network member laboratories in the
119 United States using email listservs. If publicly available information detailed that a laboratory had
120 a robust SARS-CoV-2 testing program but no response was recorded for this laboratory following
121 the survey's due date, laboratory leadership were contacted directly via email to personally invite
122 them to participate. Responses were collected between March 31, 2023 and July 18, 2023.

123 **Survey**

124 Respondents first identified the name of their laboratory and whether they conducted animal
125 SARS-CoV-2 diagnostic testing and human SARS-CoV-2 testing. Respondents who conducted
126 animal SARS-CoV-2 testing were asked 6 questions about the duration of the testing program,
127 number of animals tested, testing methodology, and if viral nucleic acid sequencing was
128 conducted. Respondents whose laboratories conducted human SARS-CoV-2 testing were asked
129 19 questions across 4 domains, including test characteristics, timeline and testing volumes, testing
130 logistics, and reflections on emergency response. For all questions respondents could either select
131 from an array of response choices or write in a response. At the end of the survey, respondents had
132 the option to include their contact information for follow-up. A copy of the survey may be found
133 in the supporting information (see S1 File).

134 **Survey analysis**

135 Responses were analyzed by descriptive statistics and qualitative analysis using Microsoft Excel
136 and R (version 2022.07.2+576 "Spotted Wakerobin"). R packages included readr, questionr, and
137 ggplot2. When curating data for analysis, duplicate laboratory responses were combined into one
138 entry. In the case of numerical response entry (e.g., date of testing commencement, number of total

139 samples tested), the numerical response that was either the most detailed (e.g., August 21, 2023
140 versus August 2023) or the largest (e.g., 1,245 samples versus 1,000 samples) was used in the final
141 response for laboratories with duplicate responses. Incomplete responses that either could not be
142 traced back to a specific institution or had no meaningful information (e.g., most questions
143 unanswered) were removed from the dataset.

144 **Semi-structured interviews with survey respondents**

145 **Source population**

146 To learn more about the specific elements of a laboratory's response, a convenience sample of
147 survey respondents were asked to participate in a semi-structured interview. Two groups of
148 interviewees were invited: (1) laboratories that conducted human SARS-CoV-2 testing and (2)
149 laboratories that did not conduct human SARS-CoV-2 testing. For the first group, invitations for
150 interview were sent to two survey respondents per region of the US (Northeast, South, Midwest,
151 and West) to include laboratories representing all US regions. Within regions, invitations for
152 interview were selected based on interesting elements of a laboratory's response (e.g., unusually
153 high testing capacity, testing methodology that differed from what was observed in most
154 responses). Based on the barriers cited by these interview respondents in group 1, laboratories in
155 group 2 were invited for interview to gain a deeper understanding of what barriers may exist in
156 conducting human SARS-CoV-2 testing. One laboratory that did not conduct human SARS-CoV-2
157 testing per US geographic region was invited to interview, except for the Midwest because all
158 laboratories that responded to the survey in this region conducted human SARS-CoV-2 testing.
159 Across both group 1 and group 2, eleven interview invitations were sent and ten interviews were
160 conducted. One invited laboratory did not respond to requests for interview.

161 **Interviews**

162 Interviews lasted approximately 30 minutes and were conducted virtually via Zoom, Microsoft
163 Teams, or by phone. Interviewees were asked about what elements of their testing program were
164 most impactful on their laboratory’s testing capacity, what barriers they experienced in either
165 setting up or operating their testing programs beyond those discussed in the survey responses, and
166 what information they would find useful for their current and future laboratory operations from
167 this publication. If time permitted, interviewees were asked for their major learning outcomes and
168 anticipated changes to pandemic preparedness following their experiences with SARS-CoV-2. For
169 interviewees whose institutions did not conduct SARS-CoV-2 testing, additional questions were
170 asked about their laboratory’s regular operations and if there was consideration of using veterinary
171 laboratory resources during their institution’s COVID-19 response. A copy of interview questions
172 may be found in the supporting information (see S2 File).

173 **Interview analysis**

174 During all but one interview, two researchers were present for interview facilitation and note
175 taking. Information revealed during interviews that provided further insight into specific
176 components of a survey response were included in the results section of this study. Themes
177 consistent across most interviews were used to inform the discussion section of this manuscript.

178 **Evaluation of publicly available information**

179 To consider experiences of laboratories who conducted SARS-CoV-2 testing but did not
180 participate in this study, public information was gathered to contextualize or provide further insight
181 for survey and interview results. Publicly available information used for this analysis included
182 peer-reviewed publications, online local or national news articles, white papers, and articles
183 published by campus news. Google, Google Scholar, and the EBSCO database were used in these
184 searches. Sample search terms included: (“SARS-CoV-2” OR “COVID19” OR “COVID-19”)

185 AND (“veterinary diagnostic” OR “animal diagnostic” OR “veterinary lab” OR “animal lab”)
186 AND (“university” OR “college” OR “school”). In some cases, when gathering information for
187 specific laboratories, the name of the institution of interest was included in the search terms.
188 Information gathered from these searches supplemented information presented in surveys or
189 interviews.

190 **Results**

191 In total, 76 invitations for participation were sent and 38 total responses were recorded, yielding a
192 response rate of 50%. All regions of the US were accounted for by respondents, with most
193 responding laboratories located in the Midwest and South (Fig 1). Thirty-three total states were
194 represented (Fig 1).

195

196 **Fig 1. Map of Survey Respondents.** Light blue represents one responding laboratory and dark
197 blue represents two responding laboratories. Visualization made using Datawrapper.

198

199 Thirty (79%) of 38 responding veterinary diagnostic laboratories were operated within a
200 university, of which 19 were operated within a college of veterinary medicine (Table 1). Eight
201 laboratories (21%) were not affiliated with a college or university (Table 1). Of the 38 survey
202 respondents, 20 (53%) conducted both animal and human SARS-CoV-2 testing, 7 conducted only
203 animal testing, 4 conducted only human testing and 7 did not conduct human or animal tests (Table
204 1). More respondents conducted only animal testing than only human SARS-CoV-2 testing (7
205 laboratories versus 4 laboratories, respectively; Table 1).

206

207 **Table 1. Organizational Structure and Distribution of Animal and Human SARS-CoV-2**
208 **Testing Among Responding Laboratories (n=38).**

Organizational structure of laboratory	Number of laboratories (%)
Operating within a college of veterinary medicine, partially/fully state funded	6 (16)
Operating within a college of veterinary medicine, not state funded	13 (34)
Operating within a university, but not a college of veterinary medicine, partially/fully state funded	5 (13)
Operated within a university, but not a college of veterinary medicine, not state funded	6 (16)
Not within a university or college of veterinary medicine, state funded	7 (18)
Not within a university or college of veterinary medicine, federally funded	1 (3)
Testing conducted	
Conducted both animal and human SARS-CoV-2 testing	20 (53)
Conducted animal SARS-CoV-2 testing but not human SARS-CoV-2 testing	7 (18)
Conducted human SARS-CoV-2 testing but not animal SARS-CoV-2 testing	4 (11)
Did not conduct animal or human SARS-CoV-2 testing	7 (18)

209
210 **Animal SARS-CoV-2 testing**

211 Most laboratories that conducted animal SARS-CoV-2 testing began testing in early 2020 (58%),
212 followed by mid-2020 (29%) and late 2020 (13%; n = 24). Furthermore, 23 (88%) surveyed
213 laboratories were continuing to test animals as of May 2023 (n = 26).

214 The species of tested animals can be broadly categorized as wildlife (e.g., moose, bobcat),
215 companion animals (e.g., cats, dogs), agricultural or farming animals (e.g., cattle, pigs), and zoo
216 animals (e.g., tigers, lions). Among survey respondents, the animal category most tested was
217 companion animals (42%), followed by wildlife and zoo animals (23% respectively; Fig 2). Farm
218 animals were the least tested animal category (13%; Fig 2). These results are consistent with the
219 United States Department of Agriculture reporting that companion animals were the main species
220 tested, followed by wildlife and zoo animals.[15]

221

222 **Fig 2. Frequency Distribution for Laboratories Testing Various Animal Species for SARS-**
223 **CoV-2 Among Survey Respondents.** Animal species were categorized into companion, farm,
224 wildlife, and zoo animals and the bars represent the number of laboratories that tested for each
225 category.

226
227 The number of animal samples tested for SARS-CoV-2 among 22 survey respondents who
228 provided these numbers ranged from 9 to 3,600 animals, although this large range may be
229 accounted for by some survey respondents including research tests in addition to clinical or
230 diagnostic tests. Furthermore, it is possible that survey respondents reported the number of SARS-
231 CoV-2 tests performed as opposed to the number of animals tested as some animals were tested
232 serially. Every laboratory that conducted animal SARS-CoV-2 testing used reverse transcription
233 polymerase chain reaction (RT-PCR) methodology for tests. In addition to RT-PCR testing, seven
234 respondents (29%) performed viral nucleic acid sequencing to gather genotypic information about
235 the viral variants.

236 **Human SARS-CoV-2 testing**

237 Of the 38 laboratories providing survey responses, 24 laboratories (63%) indicated that they
238 conducted human SARS-CoV-2 testing. Among these 24 laboratories, 14 (58%) conducted human
239 SARS-CoV-2 testing for a university population and 7 (29%) tested for the general community.
240 Three laboratories tested for both a university population and the general community (13%
241 respectively). Two laboratories conducted testing for local hospitals (8%). Fourteen of the 17
242 universities whose laboratories conducted testing for their populations had testing requirements
243 that ranged from compulsory testing among specific student populations or under certain

244 conditions (e.g., student athletes, symptomatic individuals only) to the entire population (e.g.
245 students, faculty and staff) requiring testing.

246 The most common reason for human sample testing was to increase university testing capacity (17
247 laboratories; 71%), followed by increasing testing capacity for the local community (6
248 laboratories; 25%) and testing to decrease turnaround time (5 laboratories; 21%). Furthermore, 4
249 laboratories tested to increase testing capacity for the local health departments and hospitals (17%)
250 or to provide information to local health departments through sequencing (4 laboratories, 17%).
251 Research and reducing test cost were also cited as a testing motivation.

252 As was the case for animal tests, real-time RT-PCR was the most common method of SARS-CoV-
253 2 testing and used in 22 (92%) laboratories. In addition to RT-PCR, laboratories also conducted
254 enzyme-linked immunosorbent assays and sequencing. Most real-time RT-PCR tests targeted
255 ORF1ab, spike, and nucleocapsid genes. As displayed in Fig 3, nasopharyngeal swabs were the
256 most common sample type (14 laboratories; 58%) followed by anterior nares swabs (12
257 laboratories; 50%) and saliva (10 laboratories; 42%). Only one institution collected samples from
258 nasal mid-turbinate swabs (4%) and oropharyngeal swabs (4%).

259

260 **Fig 3. Frequency Distribution of the Sample Types Tested for SARS-CoV-2 Among the 24**
261 **Laboratories Surveyed That Conducted Human Testing.**

262

263 Only 1 institution of the 24 that conducted human SARS-CoV-2 testing was responsible for sample
264 collection. At this institution, observed self-collection sampling occurred at designated campus
265 testing sites. Furthermore, one institution pooled diagnostic test samples and two laboratories
266 pooled surveillance tests. At the institution that pooled diagnostic tests, samples were pooled in

267 groups of five. When pools were positive, individual samples were tested separately following
268 deconvolution of the pools. Seventeen (74%) laboratories that tested human samples used
269 automation or robotics to achieve their testing capacity with the Kingfisher Flex most frequently
270 cited for high-throughput nucleic acid extraction. For human SARS-CoV-2 testing, 9 (39%)
271 institutions conducted viral nucleic acid sequencing to gather genotypic information about the viral
272 variants. Two of the fourteen laboratories that did not conduct viral nucleic acid sequencing sent
273 samples to state collaborators for sequencing.

274 Most laboratories began their human SARS-CoV-2 testing program in the late summer months of
275 2020. Most of these laboratories ended their testing programs mid-way through 2022, though one
276 ended as early as July 2020 and one was continuing testing until May 2023.

277 Maximum samples tested per day and total samples tested among the human SARS-CoV-2 testing
278 laboratories varied greatly across laboratories (Table 2). Across all laboratories, daily testing
279 capacity ranged from 300 to 14,000 samples tested per day, with a median of 2,000 samples per
280 day. The total number of samples tested ranged from 6,215 to 3,000,000 total samples, with a
281 median number of total samples tested of 121,546. There was no statistically significant
282 relationship between samples tested per day and result turnaround time (Spearman correlation
283 coefficient: -0.06 ; $p = 0.789 > 0.05$).

284

285 **Table 2. Summary Statistics of Daily Testing Capacity and Total Samples Tested Among**
286 **Laboratories That Conducted Human SARS-CoV-2 Testing, Stratified by Laboratories that**
287 **Used Robotics Versus Did Not Use Robotics (n = 24).**

	Minimum	Median	Maximum
Sample testing capacity per day			
Using robotics	518	2,000	14,000
Not using robotics	300	600	5,823

Total samples tested

Using robotics	6,215	472,635	3,000,000
Not using robotics	8,500	43,498	850,000

288

289 **Automation and Pooling**

290 Laboratories using robotics tested more samples per day and tested more samples total than
291 laboratories that did not use robotics (Table 2). The median number of samples tested per day was
292 2,000 for laboratories that used robotics and 600 for laboratories that did not use robotics (Table
293 2). Similarly, the median total number of samples tested for laboratories that used robotics was
294 472,635 samples versus a median number of samples of 43,498 samples for laboratories that did
295 not use robotics (Table 2).

296 While automation was used for laboratories that had higher testing capacities, automation was not
297 *essential* to achieving a high testing capacity. One laboratory reported a daily testing capacity of
298 5,823 samples tested per day without use of robotics, which is substantially higher than the median
299 daily testing capacity of 600 samples tested per day among the non-automated group. This
300 laboratory achieved this high sample testing capacity by having a large workforce totaling
301 approximately 90 full time equivalents. The laboratory tested one-third of the student body each
302 week such that the entire study body was evaluated every three weeks, enabling the university to
303 detect and address hotspots of SARS-CoV-2 cases earlier and ultimately reduce the burden of
304 SARS-CoV-2 on campus.

305 One laboratory conducted pooling for diagnostic SARS-CoV-2 tests and, using this methodology,
306 achieved a sample testing capacity of greater than 10,000 samples per day. Pooling was conducted
307 in 96-welled plates, each containing 93 pools of 5 samples. Processed samples were placed into
308 barcode-visible Biomek tube racks so that Biomek i5 could generate pools while also allowing the
309 Data Acquisition and Reporting Tool 2.0 software to record the position of each sample in the

310 pooled wells. The well position within the 96-well plate and the sample position in storage racks
311 were retained and managed through a custom software application (COVID-19 Receiving
312 App).[16] Three wells were left as controls.[16] In forty-five minutes, 465 samples were pooled
313 into 93 wells of the 96-well plate.[16] If any pools tested positive, deconvolution took place and
314 samples were tested individually.[16] Result reporting for pooled samples had a median turn-
315 around time of 4 hours and 46 minutes, although positive pools had a median turn-around time of
316 22 hours and 19 minutes.[16] Samples that were not pooled (and tested individually) had a median
317 turn-around time of 3 hours and 56 minutes.[16] Although logistically more complicated, pooling
318 increased efficiency, enabling rapid test result communication, which ultimately improved the
319 effectiveness of intervention among positive cases. Pooled testing also resulted in lower cost per
320 sample tested due to lower workforce requirements and conservation of testing reagents and
321 supplies.

322 Pooling, however, was not required to achieving a high sample testing capacity. The laboratory
323 with the highest number of samples tested of all surveyed laboratories, with a daily sample testing
324 capacity of 14,000 samples tested and 3,000,000 samples tested overall, did *not* pool samples for
325 testing. This strategy, however, involved a large number of full time FTE's and extended/double
326 shifts.

327 While some laboratories did consider pooling, one barrier to using pooling in the diagnostic
328 workflow included lack of access to the proper equipment to conduct pooling effectively. One
329 laboratory noted that the use of saliva samples and the lack of access to liquid sensing tips caused
330 the sample to dribble throughout the machine during pooling trials. Given the low population size
331 on this institution's campus during the pandemic, they decided to focus on testing optimization in
332 other areas of the testing scheme instead of pooling. A different laboratory noted that pooling was

333 not pursued because the deconvolution of positive samples would have increased testing cost and
334 sample result turnaround times. Given these barriers, the decision to pool as a mechanism of
335 increasing testing capacity was dependent on resources, such as workforce, lab supplies, and
336 budget.

337 **Barriers to testing**

338 Seventeen (71%) laboratories reported that obtaining the proper certification or licensure was an
339 initial impediment to testing human SARS-CoV-2 samples (Table 3). The Clinical Laboratory
340 Improvement Amendments (CLIA) certification was the most frequently cited barrier related to
341 licensure for testing. Limited human workforce capacity and having other organizational
342 responsibilities were also primary barriers to testing human samples (58% and 38% respectively;
343 Table 3). Three laboratories cited lack of qualified workforce and the need for constant staff
344 training to ensure consistent results as additional issues. These same laboratories also indicated
345 that managing work schedules to ensure testing capacity while preventing burn out among
346 employees was challenging. One institution stated that tripling the size of their workforce in one
347 month to accomplish SARS-CoV-2 testing was easy, as graduate students, professors, and
348 department heads took pride in volunteering for the testing initiative. Given that normal operations
349 were interrupted, many students and faculty had more time to dedicate towards a testing initiative,
350 requiring this institution to limit the number of volunteers working in the diagnostic laboratory.
351 Limited physical space for testing and obtaining funding were the least frequently reported barriers
352 to human testing (21% and 17% respectively), and none of the surveyed laboratories reported
353 achieving satisfactory testing accuracy as a barrier to testing operations (Table 3).
354 One frequently cited barrier to SARS-CoV-2 testing was institutional leadership. Four laboratories
355 noted that university administration constrained SARS-CoV-2 testing initiatives. In one case,

356 administration viewed SARS-CoV-2 as not sufficiently urgent to warrant resources to mount a
357 testing response. For this academic institution—and another institution that cited internal
358 leadership problems as a barrier to operation—there was an additional concern that reporting
359 SARS-CoV-2 numbers on campus would result in diminished enrollment in the universities. To
360 justify the need for SARS-CoV-2 testing despite these concerns, one institution reported that
361 resources were allotted to testing once a county public health agency became involved to advocate
362 for the importance of a testing program.

363 Support by human health agencies (e.g., public health agencies, human health providers) for
364 veterinary diagnostic laboratories to participate in SARS-CoV-2 response was not universal, as
365 two laboratories cited human health agencies as a barrier to developing a testing program. One
366 institution described how public health groups made the state’s granting of CLIA certification
367 difficult for the veterinary diagnostic laboratory. In this case, the institution reported that these
368 human health agencies eventually realized the positive impact that the veterinary laboratories
369 could have on achieving the testing capacity required to control the pandemic. Consequently, the
370 veterinary diagnostic laboratory began surveillance testing, resulting in a surge of the state’s
371 SARS-CoV-2 positivity rate, and then consequently the granting of CLIA licensure for the
372 laboratory to begin diagnostic testing. While this ultimate approval for diagnostic testing enabled
373 a higher testing capacity to be achieved in this state, this response was delayed.

374

375 **Table 3. Cited Barriers to Human SARS-CoV-2 Testing Operations Among Respondents (n**
376 **= 24).**

Barrier	Frequency (%)
Obtaining the proper certifications and/or licensure	17 (71)
Limited human workforce capacity	14 (58)
Other organizational responsibilities	9 (38)

Limited testing equipment, materials, and supplies	8 (33)
Other (e.g., billing insurance, IT issues, state or local leadership)	8 (33)
Difficulty coordinating with other organizations	7 (29)
Limited physical space for testing	5 (21)
Obtaining funding	4 (17)
Achieving satisfactory test accuracy	0 (0)

377

378 **Discussion**

379 Many veterinary diagnostic laboratories developed successful programs for testing human samples
380 for SARS-CoV-2, applying high throughput and high complexity diagnostic principles used in
381 their routine testing operations. A total of 8,273,602 human samples were tested by surveyed
382 laboratories participating in this study. One university's veterinary diagnostic laboratory tested
383 one-third of their university students each week to ensure that every student was tested every three
384 weeks, allowing for the identification of outbreak clusters on campus and timely intervention by
385 public health groups. Another university, early in the pandemic, determined that the student body
386 would need to be tested twice per week to allow faculty, staff and students to safely return to work
387 and school, requiring a testing capacity of 7,000 samples tested per day.[17,18] This animal
388 diagnostic laboratory, using its expertise and population testing principles and workflows
389 established a final daily testing capacity exceeding 10,000 samples with a result turnaround time
390 of 24 to 36 hours, ultimately testing 2,079,685 samples in a rural region where closure of the
391 university would have had large impacts on accessibility of testing for local community members.
392 Some veterinary diagnostic laboratories offered testing services to nearby institutions and satellite
393 campuses and consequently, some of these university testing programs, with their animal
394 population based high throughput design, made up a large proportion of total state tests. One
395 laboratory's testing capacity of 18,000 samples daily corresponded to 20% of all daily testing

396 completed in that state, and to 1.5-2.5% of all SARS-CoV-2 daily samples tested nationwide.[19]
397 One other veterinary diagnostic laboratory conducted 25% of its state’s total tests; In fact, this
398 laboratory tested four times as many SARS-CoV-2 samples than the state’s public health
399 laboratories[12] and more than any other laboratory in the state. Given these contributions,
400 veterinary diagnostic laboratories have demonstrated their importance and positive impact in
401 achieving high testing capacity on population-wide scale during public health emergencies.
402 These contributions to states’ large scale testing programs were achieved despite significant
403 challenges, with the most frequently cited obstacle being the regulatory requirements that
404 prevented veterinary diagnostic laboratories from participating either early in the pandemic or,
405 depending on states’ interpretation of rules and regulations, throughout the pandemic.
406 There were two testing options for SARS-CoV-2 laboratories: surveillance testing and diagnostic
407 testing. The Food and Drug Administration authorized surveillance testing for emergency use
408 during the SARS-CoV-2 pandemic, allowing laboratories—including veterinary diagnostic
409 laboratories—to monitor SARS-CoV-2 incidence in populations.[20] Surveillance testing,
410 however, does not permit contact tracing of detected cases (i.e. tracing back results to tested
411 individuals and determining potential infected and infectious contacts), thereby decreasing the
412 public health usefulness of surveillance testing programs.[20] To conduct diagnostic testing which
413 allows identification of the infected patient and subsequent contact tracing, laboratories must
414 obtain Clinical Laboratory Improvement Amendments (CLIA) certification with requirements that
415 were difficult, or depending on states’ interpretation, impossible to meet for veterinary diagnostic
416 laboratories. The requirement in 42 CFR §493.1443 in particular states that a laboratory director
417 must be a licensed medical professionals (i.e., Doctor of Osteopathic Medicine, Medical Doctor,
418 Doctor of Veterinary Medicine) with training and professional experience limited to human or

419 public health diagnostic testing, specifically that “[l]aboratory testing of non-human specimens is
420 not acceptable experience, e.g., environmental, animal testing.”[21] This requirement prevented
421 some veterinary diagnostic laboratories from participating at all despite their expertise, experience
422 and capacity in testing more samples with “the same machinery, scientific theory, and tests as
423 human health facilities with the only difference being the taxonomy of the sample source.”[12] A
424 case in point was that veterinary laboratory diagnosticians in one state were called upon to train
425 human health professionals to perform the testing that they themselves were not certified to
426 perform and participate in the SARS-CoV-2 testing response. Clinical Laboratory Improvement
427 Amendments (CLIA) certification thus constituted a “bureaucratic wall” in many states, requiring
428 the establishment of sometimes complex partnerships of veterinary diagnostic laboratories with
429 state or private human health partners.[22] Two interviewed laboratories obtained rapid and
430 independent certification, due to support within established networks in their State Department of
431 Health, or due to state legislators’ support, as well as strong advocacy by university leadership.
432 Most animal diagnostic laboratories, however, faced significant barriers in obtaining CLIA
433 certification due to challenges in contracting with a human health partner and strict state
434 interpretations of CLIA requirements. Differences in CLIA enforcement state-to-state certainly
435 contributed to inequities in testing resources across the country. Attitude towards diagnostic testing
436 by veterinary laboratory also constituted an obstacle in some states, despite veterinary and human
437 diagnostic laboratories using the same diagnostic methods. In fact, restrictions on one veterinary
438 diagnostic laboratory to only provide surveillance testing with confirmation of positive findings at
439 the public health laboratory were lifted within days of program commencement, resulting in lifted
440 restrictions only once the public health laboratory could not cope with the testing demand.

441 There is an urgent need when preparing for public health emergencies to reduce barriers and
442 consider available high quality testing capacity in veterinary diagnostic laboratories. Veterinary
443 diagnostic laboratories, often located in rural areas, can have a significant impact on increasing
444 accessibility to testing among rural residents. For example, the state of Washington had fifteen
445 operating SARS-CoV-2 testing laboratories. Fourteen of these laboratories were in the state’s
446 Western region, with the one animal diagnostic laboratory in the East filling an important gap in
447 accessibility to testing.

448 Despite the important role that veterinary diagnostic laboratories played in the pandemic response,
449 there is insufficient support from non-animal health institutions, ultimately impeding animal
450 diagnostic laboratory’s abilities to achieve CLIA certifications. One interviewee noted:

451 *“We, diagnostic veterinary labs, continue to see push back from public health laboratories.*
452 *The way we function, the qualifications, are equivalent to CLIA lab directors but because*
453 *of legislation we can’t just jump in and do certain things. The best outcome at a national*
454 *level to this effort and for preparedness for the future would be for vet labs to be at least*
455 *permitted on a stand-by basis to jump in without hurdles from CLIA.”*

456 This interviewee also describes how the “nation is losing out on capacity by excluding the
457 possibility that in an emergency basis, that [animal diagnostic laboratories] could jump in and get
458 going.” The SARS-CoV-2 pandemic helped convey the impact that veterinary animal
459 laboratories may have in population health emergencies despite the presence of significant
460 barriers, indicating a need for change.

461 Unfortunately, despite this need for change, on July 26, 2022, the Centers of Medicare &
462 Medicaid Services (CMS) proposed revisions to CLIA in the *Federal Register, Vol. 87, No. 142*

463 stating that they “believe that DVM should be removed from the qualifying doctoral degrees as it
464 is not relevant to testing on specimens derived from the human body” despite “CMS
465 recogniz[ing] that the COVID-19 public health emergency (PHE) requires flexibility, and [they
466 are] are committed to taking critical steps to ensure America’s clinical laboratories can respond
467 during a PHE to provide reliable testing while ensuring patient health and safety.” [9] The
468 American Association of Veterinary Laboratory Diagnosticians responded to this proposed
469 revision by stating[9]:

470 *“The incorporation of [testing by veterinary diagnostic laboratories] into the [COVID-*
471 *19 public health emergency] response was often significantly delayed due to the*
472 *inflexibility regarding recognition of [veterinary diagnostic laboratory] staff’s training,*
473 *knowledge and experience as being sufficiently equal to that mandated under CLIA. It is*
474 *paradoxical that on the heels of the strong participation [of veterinary diagnostic*
475 *institutes] in the COVID-19 [public health emergency], the new proposal actually seeks*
476 *to further restrict any recognition of veterinary training and degrees as being germane to*
477 *the oversight of diagnostic testing of human samples.”*

478 Given the undeniable and positive impact of veterinary diagnostic laboratory participation in the
479 COVID-19 response, policymakers and regulators should focus on reducing regulatory
480 impediments to enhance the Nation’s preparedness and emergency response capacity.

481 **Conclusion**

482 Veterinary diagnostic laboratories were major contributors to the Nation’s COVID-19 pandemic
483 public health response by adding to local and regional SARS-CoV-2 testing capacity and

484 assisting in “flattening the epidemic curve.” It is imperative that human health agencies and
485 federal regulators recognize these contributions and readily collaborate with and call on the
486 expertise and resources of the veterinary community and diagnostic centers as new public health
487 threats emerge. More than 60% of human infectious diseases have a zoonotic origin, which
488 underscores the urgent need to promote animal and human diagnostic collaboration under the
489 One Health umbrella in preparation for future pandemics.[23]

490 **References**

- 491 1. Chams N, Chams S, Badran R, Shams A, Araji A, Raad M, et al. COVID-19: A
492 Multidisciplinary Review. *Front Public Health* [Internet]. 2020 [cited 2023 Feb 27];8.
493 Available from: <https://www.frontiersin.org/articles/10.3389/fpubh.2020.00383>
- 494 2. Patel A. Initial Public Health Response and Interim Clinical Guidance for the 2019 Novel
495 Coronavirus Outbreak — United States, December 31, 2019–February 4, 2020. *MMWR*
496 *Morb Mortal Wkly Rep* [Internet]. 2020 [cited 2023 Feb 27];69. Available from:
497 <https://www.cdc.gov/mmwr/volumes/69/wr/mm6905e1.htm>
- 498 3. Sanche S, Lin YT, Xu C, Romero-Severson E, Hengartner N, Ke R. High Contagiousness
499 and Rapid Spread of Severe Acute Respiratory Syndrome Coronavirus 2 - Volume 26,
500 Number 7—July 2020 - *Emerging Infectious Diseases journal* - CDC. [cited 2023 Mar 8];
501 Available from: https://wwwnc.cdc.gov/eid/article/26/7/20-0282_article
- 502 4. Fenemigho I, Ukponmwan E, Nnakwue EC, Udoete I, Asuzu C, Adaralegbe A, et al.
503 COVID-19, flattening the curve: recommendations towards control and managing a second
504 wave. *J Glob Health Rep*. 2020 Aug 10;4:e2020074.

- 505 5. New COVID-19 Cases Worldwide [Internet]. Johns Hopkins Coronavirus Resource Center.
506 [cited 2023 Mar 8]. Available from: <https://coronavirus.jhu.edu/data/new-cases>
- 507 6. Population, total - Korea, Rep. | Data [Internet]. The World Bank. [cited 2023 Mar 15].
508 Available from:
509 <https://data.worldbank.org/indicator/SP.POP.TOTL?end=2021&locations=KR&start=1960>
- 510 7. Issac A, Stephen S, Jacob J, VR V, Radhakrishnan RV, Krishnan N, et al. The Pandemic
511 League of COVID-19: Korea Versus the United States, With Lessons for the Entire World.
512 J Prev Med Pub Health. 2020 Jul;53(4):228–32.
- 513 8. World Organisation for Animal Health. Veterinary Laboratory Support to the Public Health
514 Response [Internet]. 2020 [cited 2023 Mar 14]. Available from: [https://rr-
515 americas.woah.org/en/news/veterinary-laboratory-support-to-the-public-health-response/](https://rr-americas.woah.org/en/news/veterinary-laboratory-support-to-the-public-health-response/)
- 516 9. Jerry Saliki. (American Association of Veterinary Laboratory Diagnosticians). Letter to:
517 Undisclosed recipients. 2022 Sept 22.
- 518 10. Janet Donlin. (American Veterinary Medical Association). Letter to: Sarah Bennett and
519 Cindy Flacks (Centers for Medicare & Medicaid Services). 2022 Sept 23.
- 520 11. Taylor LH, Latham SM, Woolhouse ME. Risk factors for human disease emergence. Philos
521 Trans R Soc B Biol Sci. 2001 Jul 29;356(1411):983–9.
- 522 12. This veterinary lab is the linchpin in one state’s coronavirus testing approach - The
523 Washington Post [Internet]. [cited 2023 Sep 11]. Available from:

- 524 <https://www.washingtonpost.com/science/2020/05/12/this-veterinary-lab-is-linchpin-one->
525 [states-covid-19-testing-approach/](https://www.washingtonpost.com/science/2020/05/12/this-veterinary-lab-is-linchpin-one-states-covid-19-testing-approach/)
- 526 13. Cima G. Animal health laboratories aid testing for COVID-19 in people [Internet]. American
527 Veterinary Medical Association. [cited 2023 Mar 14]. Available from:
528 [https://www.avma.org/javma-news/2020-06-01/animal-health-laboratories-aid-testing-](https://www.avma.org/javma-news/2020-06-01/animal-health-laboratories-aid-testing-covid-19-people)
529 [covid-19-people](https://www.avma.org/javma-news/2020-06-01/animal-health-laboratories-aid-testing-covid-19-people)
- 530 14. Nolen RS. Veterinary labs continue to support COVID-19 testing [Internet]. American
531 Veterinary Medical Association. [cited 2023 Mar 14]. Available from:
532 [https://www.avma.org/javma-news/2020-07-01/veterinary-labs-continue-support-covid-19-](https://www.avma.org/javma-news/2020-07-01/veterinary-labs-continue-support-covid-19-testing)
533 [testing](https://www.avma.org/javma-news/2020-07-01/veterinary-labs-continue-support-covid-19-testing)
- 534 15. USDA APHIS | Cases of SARS-CoV-2 in Animals in the United States [Internet]. [cited
535 2023 Sep 11]. Available from: [https://www.aphis.usda.gov/aphis/dashboards/tableau/sars-](https://www.aphis.usda.gov/aphis/dashboards/tableau/sars-dashboard)
536 [dashboard](https://www.aphis.usda.gov/aphis/dashboards/tableau/sars-dashboard)
- 537 16. Laverack M, Tallmadge RL, Venugopalan R, Sheehan D, Ross S, Rustamov R, et al. The
538 Cornell COVID-19 Testing Laboratory: A Model to High-Capacity Testing Hubs for
539 Infectious Disease Emergency Response and Preparedness. *Viruses*. 2023 Jul;15(7):1555.
- 540 17. Ramanujan K. Cornell teams work tirelessly to limit COVID spread [Internet]. Cornell
541 Chronicle. [cited 2023 Mar 14]. Available from:
542 <https://news.cornell.edu/stories/2020/10/cornell-teams-work-tirelessly-limit-covid-spread>


- 543 18. Frazier PI, Cashore JM, Duan N, Henderson SG, Janmohamed A, Liu B, et al. Modeling for
544 COVID-19 college reopening decisions: Cornell, a case study. Proc Natl Acad Sci U S A.
545 2022 Jan 11;119(2):e2112532119.
- 546 19. U Of I Lab Working To Reduce Time To Get Results Of Saliva COVID-19 Tests [Internet].
547 NPR Illinois. 2020 [cited 2023 Sep 11]. Available from:
548 [https://www.nprillinois.org/illinois/2020-09-03/u-of-i-lab-working-to-reduce-time-to-get-](https://www.nprillinois.org/illinois/2020-09-03/u-of-i-lab-working-to-reduce-time-to-get-results-of-saliva-covid-19-tests)
549 [results-of-saliva-covid-19-tests](https://www.nprillinois.org/illinois/2020-09-03/u-of-i-lab-working-to-reduce-time-to-get-results-of-saliva-covid-19-tests)
- 550 20. Health C for D and R. FAQs on Testing for SARS-CoV-2. FDA [Internet]. 2023 Aug 16
551 [cited 2023 Sep 12]; Available from: [https://www.fda.gov/medical-devices/coronavirus-](https://www.fda.gov/medical-devices/coronavirus-covid-19-and-medical-devices/faqs-testing-sars-cov-2)
552 [covid-19-and-medical-devices/faqs-testing-sars-cov-2](https://www.fda.gov/medical-devices/coronavirus-covid-19-and-medical-devices/faqs-testing-sars-cov-2)
- 553 21. 42 CFR 493.1443 -- Standard; Laboratory director qualifications. [Internet]. [cited 2023 Sep
554 11]. Available from: <https://www.ecfr.gov/current/title-42/part-493/section-493.1443>
- 555 22. Tewari D, Zeman DH. 2020, a year to remember: AAVLD perspective. J Vet Diagn Investig
556 Off Publ Am Assoc Vet Lab Diagn Inc. 2021 May;33(3):393–5.
- 557 23. Weiss RA, Sankaran N. Emergence of epidemic diseases: zoonoses and other origins. Fac
558 Rev. 2022 Jan 18;11:2.

559 **Supporting Information**

560 **S1 File. Survey Distributed to Veterinary Diagnostic Laboratories.** Following formal survey
561 approval by the American Association of Veterinary Medical Colleges, this online cross-
562 sectional Qualtrics survey was distributed to American Association of Veterinary Medical


563 Colleges and the National Animal Health Laboratory Network member laboratories in the United
564 States.

565 **S2 File. Interview Questions.** To learn more about the specific elements of a laboratory's
566 response, a convenience sample of survey respondents were asked to participate in a semi-
567 structured interview.




Created with Datawrapper

Figure



Figure



Figure